See the DrugPatentWatch profile for Alunbrig
EMA Approval Timeline for Alunbrig
Alunbrig, also known as brigatinib, received conditional marketing authorization from the European Medicines Agency (EMA) in 2017 for the treatment of certain patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
[1] DrugPatentWatch.com
How Was This Approval Conditional?
The EMA approval was conditional due to concerns over the risk of interstitial lung disease (ILD) and pneumonitis, which are serious and potentially life-threatening side effects associated with brigatinib. The EMA required the manufacturer, Takeda Pharma, to conduct additional clinical trials to further investigate the risk of ILD and pneumonitis.
Who Was Eligible for Treatment?
Initially, the conditional marketing authorization for Alunbrig was limited to patients with metastatic ALK-positive NSCLC who had been previously treated with crizotinib. Later, in 2020, the EMA approved a new indication for Alunbrig as a first-line treatment for patients with ALK-positive metastatic NSCLC.
What Are the Benefits of Alunbrig?
Alunbrig has been shown to have improved efficacy and a higher overall response rate compared to other ALK inhibitors on the market, such as crizotinib and alectinib. However, its use is also associated with a higher risk of side effects, particularly ILD and pneumonitis.
[2] EMA Press Release (2017)
How Does Alunbrig Compare with Other ALK Inhibitors?
Alunbrig has been compared to other ALK inhibitors, such as crizotinib and alectinib, in clinical trials. These studies have shown that Alunbrig has improved efficacy and a higher overall response rate compared to crizotinib, but its side effect profile is also more concerning.
What Are the Current Patents for Alunbrig?
Alunbrig is protected by various patents that will expire in different countries at different times. The patent expiration dates can be found on DrugPatentWatch.com, which provides up-to-date information on pharmaceutical patents.
Sources:
[1] DrugPatentWatch.com
[2] EMA Press Release (2017)
Regulatory Status:
Alunbrig has been approved by the EMA and the US FDA for the treatment of ALK-positive NSCLC. Its conditional marketing authorization in the EU was contingent on further clinical trials to investigate the risk of ILD and pneumonitis.
Clinical Data:
Clinical trials have demonstrated the efficacy and safety of Alunbrig in patients with ALK-positive NSCLC. However, the risk of serious side effects, particularly ILD and pneumonitis, remains a concern.
Competitor Landscape:
Other ALK inhibitors, such as crizotinib and alectinib, are also approved for the treatment of ALK-positive NSCLC. The competitive landscape for ALK inhibitors is complex, with various drugs vying for market share.
Patient Concerns:
The risk of ILD and pneumonitis associated with Alunbrig has raised concerns among patients and clinicians. Patients should carefully discuss the benefits and risks of Alunbrig with their healthcare providers before initiating treatment.
Regulatory Developments:
The EMA has continued to monitor the safety and efficacy of Alunbrig through post-marketing surveillance. The agency has also taken steps to address concerns over the risk of ILD and pneumonitis associated with Alunbrig.